ARKG — ARK Genomic Revolution ETF

ARKG Price Performance — Growth of $10,000

Value of a $10,000 investment in ARKG over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.

ARKG Drawdown

The "underwater" chart: ARKG's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.

Overview

The ARK Genomic Revolution ETF is a healthcare-focused fund issued by ARK ETF Trust with $2.02 billion in assets. It holds a C grade and ranks 9th out of 11 peers in its category, placing it 240th among all tracked ETFs. The fund’s 0.75% expense ratio is more than double the category median of 0.36%, while its 0.00% dividend yield falls significantly below the 0.88% median. Concentration is notable, with the top ten holdings comprising 58.8% of assets and TEMPUS AI INC representing the largest single position at 9.4%.

The fund’s price of $46.85 sits at 85.8% of its 52-week range, reflecting a strong upward trajectory over the past year. Returns have accelerated sharply, with the one-year gain of 83.58% far outpacing the category median of 24.59% and the three-year average of 49.54%. This robust long-term performance contrasts with recent short-term weakness, as the fund posted declines of 0.62% over one day and 0.80% over one week. The rating was upgraded from D to C on July 29, 2026, though the fund has only three years of price history available for analysis.

With a beta of 2.37, the ETF moves more than twice as much as the broader market, contributing to its very high annualized volatility of 44.78%. Despite this elevated risk profile, the fund achieved a Sharpe ratio of 1.76, indicating that returns have compensated well for the volatility taken. The maximum drawdown of -46.45% highlights the significant downside potential inherent in its price movements. Liquidity remains robust, supported by an average daily volume of 3,657,977 shares and a tight bid-ask spread of 0.02%.

AI-generated summary based on the data on this page.

ARKG Top Holdings

Holdings as of 2026-04-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 58.8% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how ARKG's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.

Which Funds Overlap With ARKG

Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with ARKG's top 10 — ARKK overlaps most, holding 2 of the same companies as ARKG's top 10 (18.3% of ARKG's assets).

Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.

Market Backdrop

10-Year Treasury Yield: 4.78% (as of 2026-09-04) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.

CBOE Volatility Index (VIX): 15.30 (as of 2026-09-07) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.

Federal Funds Rate: 3.63% (as of 2026-08-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.

ARKG Liquidity, Domicile & Tax Treatment

Liquidity: Quoted bid/ask spread is 0.02% and average daily volume is 3.7M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $2.02B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.

Domicile & tax treatment: ARKG is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.

ARKG Performance History

How ARKG Compares to Other Healthcare ETFs